|
|
|
| Borderline resectable giant hepatic cavernous hemangioma and coexisting hemangiomatosis should be a new indication for living donor liver transplantation: A report of two cases |
| Sung-Min Kim, Deok-Bog Moon ∗, Young-In Yoon, Sung-Gyu Lee |
Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
∗ Corresponding author.
E-mail address: mdb1@amc.seoul.kr (D.-B. Moon). |
|
|
|
|
Abstract Hemangioma is a benign liver tumor that rarely requires treatment if the patient is asymptomatic [ 1 ]. However, great cavernous hemangioma (GCH) can lead to symptoms due to its mass effect and Kasabach-Merritt syndrome (KMS) [ 2 ]. GCH treatment options vary; therefore, tailoring treatment to individual patients according to their condition, such as symptoms, tumor location, and liver function, is important. Occasionally, GCH is associated with hemangiomatosis, and its boundaries with normal tissue are unclear [ 3 ], leading to a lack of consensus on the initial therapeutic approach, with literature primarily comprising case reports or series [ 4 ]. This study presented two cases of GCH and coexisting hemangiomatosis; the patients underwent liver resection of the main mass to relieve symptoms but ultimately required liver transplantation (LT). We aimed to describe the role of LT in these patients.
|
|
|
|
|
|
| [1] |
Zhou L, Zhu JQ, Kou JT, Xu WL, Lyu SC, Du GS, Yang HW, Wang JF, Hu XP, Yu CZ, Yuan CH, Han DD, Sang CQ, Li B, Gao J, Qi HZ, Wang LM, Lyu L, Liu H, Wu JY, Lang R, He Q, Li XL. Chinese expert consensus on quantitatively monitoring and assessing immune cell function status and its clinical application (2024 edition)[J]. Hepatobiliary Pancreat Dis Int, 2024, 23(6): 551-558. |
|
|
|
|
2024, Vol. 23 
